BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 8895522)

  • 1. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
    Albor A; Thraves PJ; Dritschilo A; Notario V
    Oncogene; 1996 Oct; 13(8):1755-63. PubMed ID: 8895522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The trk family of oncogenes and neurotrophin receptors.
    Lamballe F; Klein R; Barbacid M
    Princess Takamatsu Symp; 1991; 22():153-70. PubMed ID: 1844238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene.
    Greco A; Fusetti L; Miranda C; Villa R; Zanotti S; Pagliardini S; Pierotti MA
    Oncogene; 1998 Feb; 16(6):809-16. PubMed ID: 9488046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor.
    Lavenius E; Gestblom C; Johansson I; Nånberg E; Påhlman S
    Cell Growth Differ; 1995 Jun; 6(6):727-36. PubMed ID: 7669728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.
    Greco A; Pierotti MA; Bongarzone I; Pagliardini S; Lanzi C; Della Porta G
    Oncogene; 1992 Feb; 7(2):237-42. PubMed ID: 1532241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of human trk proto-oncogene product monoclonal antibodies.
    Eager KB
    Oncogene; 1991 May; 6(5):819-24. PubMed ID: 2052359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 associates with trk tyrosine kinase.
    Montano X
    Oncogene; 1997 Jul; 15(3):245-56. PubMed ID: 9233759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of conserved residues in the tyrosine kinase domain of the human trk oncogene.
    Mitra G
    Oncogene; 1991 Dec; 6(12):2237-41. PubMed ID: 1837350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic activation of murine mos protein kinase by DNA rearrangement of its N-terminal coding region.
    Ohuchi T; Kurita Y; Sasai H; Miyoshi J; Nomura T; Toyoshima K
    Oncogene; 1992 Feb; 7(2):331-8. PubMed ID: 1532243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and function of the nerve growth factor receptor (TRK-A) in human neuroblastoma cell lines.
    Azar CG; Scavarda NJ; Nakagawara A; Brodeur GM
    Prog Clin Biol Res; 1994; 385():169-75. PubMed ID: 7972209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation.
    Roccato E; Pagliardini S; Cleris L; Canevari S; Formelli F; Pierotti MA; Greco A
    Oncogene; 2003 Feb; 22(6):807-18. PubMed ID: 12584559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and expression of human c-Ha-ras and c-sis sequences in NIH3T3 transformants.
    Weismanová E; Sabová L
    Neoplasma; 1990; 37(6):675-85. PubMed ID: 2274086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes.
    Greco A; Mariani C; Miranda C; Pagliardini S; Pierotti MA
    Genomics; 1993 Nov; 18(2):397-400. PubMed ID: 8288244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors.
    Tapley P; Lamballe F; Barbacid M
    Oncogene; 1992 Feb; 7(2):371-81. PubMed ID: 1312698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes.
    Greco A; Miranda C; Pagliardini S; Fusetti L; Bongarzone I; Pierotti MA
    Genes Chromosomes Cancer; 1997 Jun; 19(2):112-23. PubMed ID: 9172002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors.
    Schneider R; Schweiger M
    Oncogene; 1991 Oct; 6(10):1807-11. PubMed ID: 1656363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of structure and activation of some receptor-type tyrosine kinase oncogenes.
    Shibuya M; Matsushime H; Yamazaki H; Wang LH; Fukui Y; Ueyama Y; Tamaoki N
    Princess Takamatsu Symp; 1986; 17():195-202. PubMed ID: 3455414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.
    Butti MG; Bongarzone I; Ferraresi G; Mondellini P; Borrello MG; Pierotti MA
    Genomics; 1995 Jul; 28(1):15-24. PubMed ID: 7590742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
    Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human hst-2 (FGF-6) oncogene: cDNA cloning and characterization.
    Iida S; Yoshida T; Naito K; Sakamoto H; Katoh O; Hirohashi S; Sato T; Onda M; Sugimura T; Terada M
    Oncogene; 1992 Feb; 7(2):303-9. PubMed ID: 1549352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.